Last edition
News about "Type 2 Diabetes"
UK MHRA Approves Wegovy for Treatment of MASH in Adults with Liver Fibrosis
The UK's Medicines and Healthcare products Regulatory Agency has conditionally approved Novo Nordisk's Wegovy (semaglutide) for treating metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis, subject to ongoing confirmatory clinical data.
Type 2 Diabetes | 06/07/2026 | By News Bureau
Lilly's Oral GLP-1 Foundayo Shows Superior A1C Control and Weight Loss in Type 2 Diabetes
Lilly’s oral GLP-1 drug Foundayo (orforglipron) delivered superior A1C control and weight loss in 3 pivotal Type 2 Diabetes (T2D) trials, outperforming oral semaglutide and helping more patients achieve glycemic targets.
Type 2 Diabetes | 10/06/2026 | By News Bureau | 102
Abbott has received CE Mark approval for Libre Duo, the world’s first dual glucose-ketone sensing technology, offering continuous monitoring of both glucose and ketone levels to help prevent diabetic ketoacidosis and support safer diabetes care.
Type 2 Diabetes | 30/05/2026 | By News Bureau
MindRank Doses First Patient in Phase III Trial of AI-Designed Oral GLP-1RA MDR-001 in China
MindRank has initiated its Phase III MOBILE trial of MDR-001, an AI-designed oral GLP-1 receptor agonist, evaluating long-term efficacy and safety in 750 obesity and type 2 diabetes patients in China.
Type 2 Diabetes | 02/03/2026 | By News Bureau | 493
UK MHRA Updates Safety Information on Semaglutide Over Rare NAION Vision Risk
UK MHRA flags a very rare risk of NAION linked to semaglutide, urging patients to seek immediate medical attention for sudden changes in vision.
Type 2 Diabetes | 07/02/2026 | By News Bureau | 604
Eli Lilly And Cipla Partner to Distribute Yurpeak (Tirzepatide) in India
Eli Lilly and Cipla have signed an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak.
Type 2 Diabetes | 27/10/2025 | By Dineshwori | 604
FDA Approves Oral Semaglutide by Novo Nordisk for CV Risk Reduction in Adults with Type 2 Diabetes
Rybelsus (Semaglutide) tablets, available in 7 mg and 14 mg doses, is the only FDA-approved oral GLP-1 therapy, and is now indicated to lower the risk of Major Adverse Cardiovascular Events (MACE)—including CV death, heart attack, or stroke—in adults with type 2 diabetes at high cardiovascular risk.
Type 2 Diabetes | 21/10/2025 | By Dineshwori | 337
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy